- Home
- NEOV vs NRXS Comparison
NEOV vs NRXS Comparison
Compare NEOV & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NEOV | NRXS |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Miscellaneous | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.7M | 78.9M |
| IPO Year | 2022 | 2023 |
Fundamental Metrics
Financial Performance| Metric | NEOV | NRXS |
|---|---|---|
| Price | $3.81 | $6.06 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | ★ 1.9M | 80.5K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.13 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,426,835.00 | $3,569,282.00 |
| Revenue This Year | $150.56 | $172.91 |
| Revenue Next Year | $5.31 | $115.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 218.59 | 32.89 |
| 52 Week Low | $1.36 | $2.21 |
| 52 Week High | $7.13 | $9.33 |
Technical Indicators
Market Signals| Indicator | NEOV | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 60.50 | 42.39 |
| Support Level | $3.51 | $6.04 |
| Resistance Level | $3.85 | $7.37 |
| Average True Range (ATR) | 0.34 | 0.24 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 62.51 | 43.89 |
Price Performance
Historical ComparisonAbout NEOV NeoVolta Inc.
NeoVolta Inc is engaged in designing, manufacturing and sale of high end Energy Storage System which can store and use solar energy via batteries and an inverter at a residential site. Its market place includes solar industry, installers, new construction homebuilders, home remodelers and homeowners.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).